Current Alzheimer research, 8(2), 203-212 (2011-01-13)
EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer's Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor. This
[Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
Progress in neuro-psychopharmacology & biological psychiatry, 8(4-6), 785-788 (1984-01-01)
The efficacy of coupling between the benzodiazepine receptor and chloride channel as well as the coupling to the GABA receptor is differentially affected by different benzodiazepine ligands. In general, the order of efficacy with regard to allosteric effects of benzodiazepine
Anxioselective anxiolytics.
M Williams
Journal of medicinal chemistry, 26(5), 619-628 (1983-05-01)
European journal of pharmacology, 634(1-3), 95-100 (2010-03-13)
Etazolate is a phosphodiesterase 4 (PDE4) inhibitor and GABAA receptor modulator that also stimulates alpha-secretase activity and neurotrophic soluble amyloid precursor protein (sAPPalpha) production, currently developed as a possible Alzheimer's disease therapeutic. In this study two doses of etazolate were
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
